Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis

Journal of Clinical Gastroenterology

Volumn 42, Issue 6, 2008, Pages 734-737

  Floreani, Annarosa ^a,c   Baldo, Vincenzo ^b   Rizzotto, Erik Rosa ^a   Carderi, Isabella ^a   Baldovin, Tatjana ^b   Minola, Eliseo ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Department of Infectious Disease ^*  (Italy)

Author keywords

Cirrhosis; HCV; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; PEG-INTRON; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BIOASSAY; BLOOD TOXICITY; BODY MASS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFORMED CONSENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; LIVER TUMOR; MIDDLE AGED; RECURRENT DISEASE; STATISTICAL MODEL;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 54749091723     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318046ea75     Document Type: Article

References (12)

1. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-739.
2. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
3. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346: 1051-1055.
4. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-147.
5. Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998;83:901-909.
6. Lau DT, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998; 28:1121-1127.
7. Hino K, Kitase A, Satoh Y, et al. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat. 2002;9:370-376.
8. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol. 2003;237(suppl):47-51.
9. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45: 579-587.
10. Hung C-H, Lee C-M, Lu S-N, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-414.
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22: 696-699.
12. EASL International Consensus Conference on Hepatitis C Paris. 26-27 February 1999 Consensus Statement. J Hepatol. 1999;31: S3-S8.